MNDR FY2026 Results: Gross Margin Expands as Net Loss Narrows

Mobile-health Network Solutions (NASDAQ: MNDR) reported FY2026 revenue of approximately US$7.74 million, up 1.2% year over year, while its net loss narrowed 9.7% to US$3.19 million for the fiscal year ended June 30, 2026. Gross profit grew substantially faster than revenue, lifting gross margin to 21.2% from 16.7%.

Core Financial Results

Revenue growth was limited, but gross profit and the bottom line improved more meaningfully. The spread between revenue growth of 1.2% and gross profit growth of 28.3% was the most important financial feature of the year.

The release did not provide EPS, cash flow, or balance-sheet figures.

Business and Segment Performance

Telemedicine revenue increased 3.9%, outpacing consolidated revenue growth and providing the main source of resilience. That gain was partially offset by lower sales in the medicines and medical-device segment, although MNDR did not disclose segment revenue amounts or margins.

MNDR also continued deploying proprietary AI-based patient engagement and clinical support tools within its MaNaDr platform. Management said these investments improved operating efficiency, patient engagement, and platform capabilities, but the release did not quantify their revenue contribution or cost savings.

Higher-Margin Services Helped Narrow the Loss

MNDR attributed the gross margin increase to a continued shift toward higher-margin services and operating efficiencies. Gross margin expanded by about 4.5 percentage points, allowing gross profit to rise much faster than the top line.

Operating expenses increased 2.3% as MNDR invested in technology, product innovation, and geographic expansion. Because that increase was considerably slower than gross profit growth, the net loss narrowed, although the company remained unprofitable with a US$3.19 million annual loss.

AI, Ghana, and the MaNaDr Ecosystem

MNDR is preparing to enter Ghana through its collaboration with the Jospong Group of Companies. The initiative remained in the operational setup and preparation stage, with services expected to roll out progressively after implementation work and local regulatory requirements are completed.

The MaNaDr Health Operating Ecosystem was scheduled for an initial Singapore launch on November 2, 2026, followed by a phased international rollout. Developed over more than two and a half years, the platform combines virtual care, clinic management, electronic medical records, patient engagement, pharmacy services, healthcare logistics, and proprietary AI tools such as Phi GPT and Aiko.

Management views the ecosystem as a scalable foundation for entering additional markets and supporting healthcare providers. However, MNDR did not provide quantitative revenue, profit, or adoption targets for the rollout.

Risks Investors Need to Watch

• Losses remain: Margin improvement reduced the net loss, but MNDR still recorded a US$3.19 million loss in FY2026.
• Mixed segment performance: Telemedicine growth was partly offset by declining medicine and medical-device sales, limiting consolidated revenue growth.
• Investment-related expense pressure: Spending on technology, product development, and geographic expansion contributed to higher operating expenses while the company remained unprofitable.
• Ghana execution and regulation: Commercial rollout depends on completing implementation activities and satisfying local regulatory requirements.
• Ecosystem commercialization: The MaNaDr rollout is central to management’s growth strategy, but its financial contribution has not yet been quantified.

Summary

FY2026 was primarily a margin-improvement year for MNDR rather than a period of rapid revenue growth. A higher-margin service mix and operating efficiencies lifted gross profit and narrowed the net loss, while weaker medicine and medical-device sales limited the top line. The next operational tests are whether MNDR can commercialize its integrated ecosystem, complete the Ghana market entry, and control expenses while pursuing expansion.